Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma
Collectively, this study elucidates some of the genetic mechanisms contributing to the progression of rrDLBCL and suggests that the presence of <i>CD58</i> mutations might serve as a powerful predictive marker for relapse/refractory outcomes in primary DLBCL patients.
Authors
- Xiaoyan Ke (ORCID: https://orcid.org/0000-0002-2195-5397)
- Lei Tian (ORCID: https://orcid.org/0000-0001-6591-0425)
- Yu Guo (ORCID: https://orcid.org/0000-0002-8886-0106)
- Shuhan Tang (ORCID: https://orcid.org/0000-0002-4978-2360)
- Hongmei Jing
- Jing Wang (ORCID: https://orcid.org/0000-0001-9981-5530)
- Wei Zhao (ORCID: https://orcid.org/0000-0003-0319-1722)
- Weilong Zhang (ORCID: https://orcid.org/0009-0009-4052-200X)
- Chaoling Wu (ORCID: https://orcid.org/0000-0002-4517-0818)
- Yuansheng Lin (ORCID: https://orcid.org/0009-0007-6178-5154)
Institutions
- Peking University (CN)
- Peking University Third Hospital (CN)
Publication Details
- Journal
- Journal of Blood Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/jbm.s471639
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Peking University
- Peking University Third Hospital